Home Stock

Stock Research: Panion & Bf Biotech

Independent, rules-based stock research to judge this stock's true performance: Cut through market noise and find high-growth or high-value gems from 8,000+ stocks worldwide.

Panion & Bf Biotech

TAI:1760 TW0001760007
49
  • Value
    16
  • Growth
    79
  • Safety
    Safety
    49
  • Combined
    47
  • Sentiment
    57
  • 360° View
    360° View
    49
Unlock
What factors are driving this 360° View?
Subscribe to View
Company Description

PANION & BF BIOTECH INC. manufactures and sells western medicines, experimental drugs, and cosmetics. The company also offers formula food, medical devices, animal and pet drugs, feed, and environmental health drugs, in addition to biotechnology services. It operates in the pharmaceuticals, cosmetics, and biotechnology industries. Its primary markets are Taiwan, mainland China, Hong Kong, and Macau. In the last fiscal year, the company had a market cap of $211 million, profits of $33 million, and revenue of $62 million. The number of employees is not available.

more

ANALYSIS: With an Obermatt 360° View of 24 (better than 24% compared with alternatives), overall professional sentiment and financial characteristics for the stock Panion & Bf Biotech are critical, mostly below average. The 360° View is based on consolidating four consolidated indicators, with three out of four indicators below average for Panion & Bf Biotech. The consolidated Growth Rank has a good rank of 81, which means that the company experiences above-average growth momentum when looking at financial metrics such as revenue, profit, and invested capital growth, as well as stock returns. It ranks higher than 81% of competitors in the same industry. The other indicators are below average, namely the Value, Safety, and Sentiment Ranks.The Value Rank at 10 means that the share price of Panion & Bf Biotech is on the high side compared with its peers regarding revenues, profits, and invested capital. The stock price is higher than for 90% of alternative stocks in the same industry. The consolidated Safety Rank has a riskier rank of 48, which means that the company has a riskier financing structure than 52% comparable companies when looking at the amount of its debt, its refinancing requirements, and its ability to service debt. The consolidated Sentiment Rank also has a low rank of 22, indicating professional investors are more pessimistic about the stock than for 78% of alternative investment opportunities. ...read more

more
Strongest Rank Analyst Opinions
Weakest Rank Liquidity
Country Taiwan
Industry Pharmaceuticals
Size Small
Website pbf.com.tw
Index
Panion & Bf Biotech stock price by TradingView. Not sourced by Obermatt.
Similar Add to Watchlist Similar See Similar Stocks
The higher the 360° View, the better the stock performed against its peers, considering all metrics. The 360° View represents an average of the other 5 ranks and is then scaled to a rank from 1 to 100. The shaded values are illustrative only.
Last update: 26-May-2026.

Make Sense of the Ranks

The higher, the better. For every stock, we judge its performance against its peers and rank it on a scale of 1 to 100. These ranks are percentiles: a rank of 75 means the company outperforms 75% of its peers in that specific area. The higher the rank, the better the stock stacks up against its peers.

Value
Identifies how good a value the stock is.
Good Value Expensive
Combined
Consolidated view across Value, Growth, and Safety.
Good Tread Carefully
Growth
Shows a company's growth potential.
High Growth Tough Times
Sentiment
Shows what the market thinks of a stock.
Positive Sentiment Skepticism
Safety
Safety
Assesses how financially secure a company is.
Well-Financed High Leverage
360° View
360° View
Holistic stock analysis: all key non-/financial metrics
Good Watch Out

Detailed and Historical Ranks

Deep dive into 15 detailed ranks and 3 years of history. Unlock the analysis.

Unlock Ranks

Unlock all 15 detailed ranks and historical data for 6,500+ stocks.

Subscribe to Unlock
Metrics Current 2025 2024 2023
Value
16 24 28 29
Growth
79 10 71 69
Safety
Safety
49 18 32 14
Sentiment
57 46 37 65
360° View
360° View
49 1 32 29
Unlock Similar Stocks

Unlock all 15 detailed ranks and historical data for 6,500+ stocks.

Subscribe to Unlock
Metrics Current 2025 2024 2023
Analyst Opinions
1 12 20 24
Opinions Change
50 50 50 50
Pro Holdings
n/a 28 24 90
Market Pulse
51 100 100 n/a
Sentiment
57 46 37 65
Unlock Similar Stocks

Unlock all 15 detailed ranks and historical data for 6,500+ stocks.

Subscribe to Unlock
Metrics Current 2025 2024 2023
Value
16 24 28 29
Growth
79 10 71 69
Safety Safety
49 18 32 14
Combined
47 1 37 24
Unlock Similar Stocks

Unlock all 15 detailed ranks and historical data for 6,500+ stocks.

Subscribe to Unlock
Metrics Current 2025 2024 2023
Price vs. Sales (P/S)
25 26 22 31
Price vs. Earnings (P/E)
43 17 33 53
Price vs. Book (P/B)
23 17 16 20
Dividend Yield
1 52 57 33
Value
16 24 28 29
Unlock Similar Stocks

Unlock all 15 detailed ranks and historical data for 6,500+ stocks.

Subscribe to Unlock
Metrics Current 2025 2024 2023
Revenue Growth
75 6 89 47
Profit Growth
75 18 59 7
Capital Growth
61 46 70 78
Stock Returns
19 36 9 81
Growth
79 10 71 69
Unlock Similar Stocks

Unlock all 15 detailed ranks and historical data for 6,500+ stocks.

Subscribe to Unlock
Metrics Current 2025 2024 2023
Leverage
52 30 43 1
Refinancing
16 11 17 13
Liquidity
84 28 67 39
Safety Safety
49 18 32 14

Similar Stocks

Discover high‑ranked alternatives to Panion & Bf Biotech and broaden your portfolio horizons.

Tripod Technology

TAI:3044
Country: Taiwan
Industry: Electronic Components
Size: Medium
Full Stock Analysis

WPG

TAI:3702
Country: Taiwan
Industry: Technology Distributors
Size: Large
Full Stock Analysis

Nippon Shinyaku

TYO:4516
Country: Japan
Industry: Pharmaceuticals
Size: Large
Full Stock Analysis

Tsumura

TYO:4540
Country: Japan
Industry: Pharmaceuticals
Size: Large
Full Stock Analysis

Frequently Asked
Questions

The only positive is high growth. The stock is expensive (low Value Rank), risky to finance, and carries critical professional sentiment. This is a risky proposition. Avoid unless you have exceptional conviction that the growth alone will overcome the price and financial risks.

Obermatt provides unbiased stock analysis as a completely independent third party. We have no conflicts of interest with individual stock titles. Our data-driven analysis is based on algorithms honed over twelve years, giving you analysis that is free from personal bias and conflicts of interest.

The 360° View Rank indicates a company's overall performance across all major financial and non-financial metrics tracked by Obermatt. A 360° View Rank of 75 means the company is more well-rounded than 75% of similar companies. A high score indicates that the company is strong across the board; it is attractively priced, growing sustainably, financially stable, and well-regarded by the market. Learn more.

Become an Obermatt subscriber and see all of the similar stocks here.

OTHER FEATURES

Use the Platform to its Fullest

The Obermatt Advantage

Ready to Elevate Your Investing?
Get Started Today

Choose the Obermatt subscription that best fits your needs.


30-day money back guarantee. Your subscription will renew until you cancel it, which you can do at any time.

What Our Customers Say

See how Obermatt improved their investing:

Review us See More Google Reviews